Patients with R/R AML treated with this were reported to have CRc rates of 31%, including 26% in those with ELN adverse disease and 64% of those with FLT3-ITD, with minimal additive myelosuppression beyond that of AZA/VEN. Here, FLT3 is linked to acute myeloid leukemia.